Avastin Takes One Step Forward, One Step Back At ASCO
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech’s bevacizumab was the subject of one study supporting use in cervical cancer and one failing to show an effect in first-line brain cancer. A separate study repeated the disappointing brain cancer results, but the sponsor sees a silver lining in the quality of life dataset.